Health Canada's veterinary drugs directorate has launched a stakeholder consultation on how Canada should handle the regulatory oversight of investigational canine longevity drugs. The consultation was announced through the directorate's standard bulletin channel rather than via press release, which is consistent with the directorate's usual approach but means the consultation has so far attracted relatively little attention outside the immediate veterinary community.

The consultation document asks for input on five specific questions. How should the directorate weigh foreign approvals from the FDA-CVM and EMA in its own review process? What should the post-marketing surveillance requirements look like for a chronic-use medication intended for healthy dogs? What guidance should the directorate provide to provincial veterinary colleges about the standard of care for owners asking about these drugs ahead of any Canadian approval? What import controls, if any, should apply to personally imported supply for owners who want to enroll their dogs in foreign access programmes? And what data-sharing arrangements should be established with the academic veterinary community to ensure Canadian dogs in any approved programme contribute meaningfully to the knowledge base?

The consultation is open to written submissions through the end of next quarter. Industry sponsors are expected to file detailed submissions, as are several Canadian veterinary professional bodies. The directorate has indicated that owner-facing organizations and individual owners are also welcome to contribute, though the format guidance is geared toward professional submissions.

This is the kind of regulatory groundwork that tends not to generate headlines but ends up shaping the actual prescribing experience years later. Canadian owners who want a substantive voice in the eventual rollout should consider contributing — either individually or through one of the owner-facing organizations that will be coordinating responses.

We'll publish a plain-English summary of the consultation document and its key questions on the regulatory-status page within the next two weeks, along with information on how to submit input.